Tempus AI, Inc.

Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence and machine learning to advance precision medicine. It builds platforms and provides next-generation diagnostics across key areas including oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company's offerings encompass genomics services such as next-generation sequencing, polymerase chain reaction testing, molecular genotyping, and anatomic pathology; extensive clinical and molecular data libraries; and AI applications like the Next platform, which uses machine learning to analyze patient data, identify care gaps, and support clinical decision-making. Tempus AI, Inc. also develops software as a medical device, including FDA-cleared tools like ECG-Low EF for detecting low ejection fraction and generative AI co-pilots integrated into electronic health records. Its solutions assist pharmaceutical and biotech firms in drug development, target discovery, treatment evaluation, and clinical trials by harnessing vast datasets for personalized care. Founded in 2015 and headquartered in Chicago, Illinois, Tempus AI, Inc. plays a pivotal role in transforming healthcare through data-driven insights and AI-powered diagnostics.